The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.
ClinicalTrials.gov identifier: NCT01657942
Principal Investigator: Steve S. Raman, MD, FSAR, FSIR
Contact: Victoria Rueda, MPH, 310-794-8334, [email protected]
If interested, please check out the eligibility criteria.
The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.
ClinicalTrials.gov Identifier: NCT01833806
Principal Investigator: David Lu, MD
Contact: Victoria Rueda, 310-794-8334, [email protected]
If interested, please check out the eligibility criteria and contact the study coordinator for more information.
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection.
ClinicalTrials.gov Identifier: NCT01888198
Principal Investigator: Matthew Rettig, MD
Contact: Steve Raman, MD
If interested, please check out the eligibility criteria and contact the study coordinator for more information.
